View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsBRAIN Biotech 배당 및 자사주 매입배당 기준 점검 0/6BRAIN Biotech 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-14.6%자사주 매입 수익률총 주주 수익률-14.6%미래 배당 수익률0%배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 29+ 1 more updateBRAIN Biotech AG to Report Fiscal Year 2025 Results on Jan 14, 2026BRAIN Biotech AG announced that they will report fiscal year 2025 results on Jan 14, 2026공시 • May 21BRAIN Biotech AG (XTRA:BNN) acquired remaining minority stake in Breatec B.V.BRAIN Biotech AG (XTRA:BNN) acquired remaining minority stake in Breatec B.V. on May 20, 2025. With the closure of this transaction, all businesses in the BRAINBiocatalysts division are now fully owned by BRAIN Biotech AG. BRAIN Biotech AG (XTRA:BNN) completed the acquisition of remaining minority stake in Breatec B.V. on May 20, 2025.공시 • Feb 06BRAIN Biotech AG, Annual General Meeting, Mar 18, 2025BRAIN Biotech AG, Annual General Meeting, Mar 18, 2025, at 10:00 W. Europe Standard Time.공시 • Jan 19BRAIN Biotech AG to Report Q3, 2025 Results on Aug 28, 2025BRAIN Biotech AG announced that they will report Q3, 2025 results on Aug 28, 2025공시 • Aug 30BRAIN Biotech AG to Report First Half, 2025 Results on May 28, 2025BRAIN Biotech AG announced that they will report first half, 2025 results on May 28, 2025공시 • May 07BRAIN Biotech AG to Report Q1, 2025 Results on Feb 26, 2025BRAIN Biotech AG announced that they will report Q1, 2025 results on Feb 26, 2025공시 • Mar 22BRAIN Biotech AG to Report Fiscal Year 2024 Results on Jan 15, 2025BRAIN Biotech AG announced that they will report fiscal year 2024 results on Jan 15, 2025공시 • Sep 03BRAIN Biotech AG to Report Nine Months, 2024 Results on Aug 29, 2024BRAIN Biotech AG announced that they will report nine months, 2024 results on Aug 29, 2024공시 • Aug 08BRAIN Biotech AG to Report First Half, 2024 Results on May 28, 2024BRAIN Biotech AG announced that they will report first half, 2024 results on May 28, 2024공시 • May 26+ 2 more updatesBRAIN Biotech AG to Report Q1, 2024 Results on Feb 28, 2024BRAIN Biotech AG announced that they will report Q1, 2024 results on Feb 28, 2024공시 • May 25BRAIN Biotech AG (XTRA:BNN) acquired remaining 17.8% stake in Biocatalysts Limited.BRAIN Biotech AG (XTRA:BNN) acquired remaining 17.8% stake in Biocatalysts Limited on May 24, 2023. The minority stake purchases have been financed from existing BRAIN Biotech's cash reserves and from new debt.BRAIN Biotech AG (XTRA:BNN) completed the acquisition of remaining 17.8% stake in Biocatalysts Limited on May 24, 2023.공시 • Jan 11BRAIN Biotech AG to Report Fiscal Year 2022 Results on Jan 16, 2023BRAIN Biotech AG announced that they will report fiscal year 2022 results on Jan 16, 2023공시 • Jan 10BRAIN Biotech AG Announces Executive ChangesBRAIN Biotech AG announced the appointments of two key leadership positions at its corporate site in Zwingenberg, headquarters and core biotechnology R&D campus of the international BRAIN Group. Following the announcement in October 2022, to establish an independent division for BRAIN Biotech AG's proprietary CRISPR technology announced that Dr. Alexander Pelzer will succeed Dr. Michael Krohn as Head of Research & Development. Dr. Krohn will now fully focus on his new leadership role with Akribion Genomics. Dr. Pelzer was previously Unit Head Enzymes & Biocatalysts at the company and has been with BRAIN Biotech for almost nine years. Dr. Pelzer enjoyed a broad education in biocatalysis, microbiology and molecular biology at the Research Centre Juelich with a focus on industrial enzyme technology. In addition to his experience in relevant fields, he demonstrated strong leadership skills along his whole career path. In addition, Dr. Martin Langer will expand his current business development responsibilities and will be appointed Managing Director and Executive Vice President of the BioScience segment at the Zwingenberg site. Dr. Langer was one of the first employees at BRAIN Biotech and accordingly has several decades of corporate experience. Alexander Pelzer and Martin Langer will take joint responsibility for further developing the R&D center in Zwingenberg into a customer-preferred provider for integrated biotechnology solutions.공시 • Nov 04BRAIN Biotech AG, Annual General Meeting, Mar 08, 2023BRAIN Biotech AG, Annual General Meeting, Mar 08, 2023.Breakeven Date Change • Oct 01Forecast to breakeven in 2025The 4 analysts covering BRAIN Biotech expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €5.08m in 2025. Average annual earnings growth of 73% is required to achieve expected profit on schedule.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 BNND 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: BNND 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장BRAIN Biotech 배당 수익률 vs 시장BNND의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (BNND)n/a시장 하위 25% (GB)2.2%시장 상위 25% (GB)5.6%업계 평균 (Chemicals)3.7%분석가 예측 (BNND) (최대 3년)0%주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 BNND 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 BNND 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 BNND 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: BNND 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YGB 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2022/12/19 23:38종가2022/09/21 00:00수익2022/06/30연간 수익2021/09/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스BRAIN Biotech AG는 8명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Yi-Dan WangDeutsche BankJan KochDeutsche BankJan KochDeutsche Bank5명의 분석가 더 보기
공시 • May 29+ 1 more updateBRAIN Biotech AG to Report Fiscal Year 2025 Results on Jan 14, 2026BRAIN Biotech AG announced that they will report fiscal year 2025 results on Jan 14, 2026
공시 • May 21BRAIN Biotech AG (XTRA:BNN) acquired remaining minority stake in Breatec B.V.BRAIN Biotech AG (XTRA:BNN) acquired remaining minority stake in Breatec B.V. on May 20, 2025. With the closure of this transaction, all businesses in the BRAINBiocatalysts division are now fully owned by BRAIN Biotech AG. BRAIN Biotech AG (XTRA:BNN) completed the acquisition of remaining minority stake in Breatec B.V. on May 20, 2025.
공시 • Feb 06BRAIN Biotech AG, Annual General Meeting, Mar 18, 2025BRAIN Biotech AG, Annual General Meeting, Mar 18, 2025, at 10:00 W. Europe Standard Time.
공시 • Jan 19BRAIN Biotech AG to Report Q3, 2025 Results on Aug 28, 2025BRAIN Biotech AG announced that they will report Q3, 2025 results on Aug 28, 2025
공시 • Aug 30BRAIN Biotech AG to Report First Half, 2025 Results on May 28, 2025BRAIN Biotech AG announced that they will report first half, 2025 results on May 28, 2025
공시 • May 07BRAIN Biotech AG to Report Q1, 2025 Results on Feb 26, 2025BRAIN Biotech AG announced that they will report Q1, 2025 results on Feb 26, 2025
공시 • Mar 22BRAIN Biotech AG to Report Fiscal Year 2024 Results on Jan 15, 2025BRAIN Biotech AG announced that they will report fiscal year 2024 results on Jan 15, 2025
공시 • Sep 03BRAIN Biotech AG to Report Nine Months, 2024 Results on Aug 29, 2024BRAIN Biotech AG announced that they will report nine months, 2024 results on Aug 29, 2024
공시 • Aug 08BRAIN Biotech AG to Report First Half, 2024 Results on May 28, 2024BRAIN Biotech AG announced that they will report first half, 2024 results on May 28, 2024
공시 • May 26+ 2 more updatesBRAIN Biotech AG to Report Q1, 2024 Results on Feb 28, 2024BRAIN Biotech AG announced that they will report Q1, 2024 results on Feb 28, 2024
공시 • May 25BRAIN Biotech AG (XTRA:BNN) acquired remaining 17.8% stake in Biocatalysts Limited.BRAIN Biotech AG (XTRA:BNN) acquired remaining 17.8% stake in Biocatalysts Limited on May 24, 2023. The minority stake purchases have been financed from existing BRAIN Biotech's cash reserves and from new debt.BRAIN Biotech AG (XTRA:BNN) completed the acquisition of remaining 17.8% stake in Biocatalysts Limited on May 24, 2023.
공시 • Jan 11BRAIN Biotech AG to Report Fiscal Year 2022 Results on Jan 16, 2023BRAIN Biotech AG announced that they will report fiscal year 2022 results on Jan 16, 2023
공시 • Jan 10BRAIN Biotech AG Announces Executive ChangesBRAIN Biotech AG announced the appointments of two key leadership positions at its corporate site in Zwingenberg, headquarters and core biotechnology R&D campus of the international BRAIN Group. Following the announcement in October 2022, to establish an independent division for BRAIN Biotech AG's proprietary CRISPR technology announced that Dr. Alexander Pelzer will succeed Dr. Michael Krohn as Head of Research & Development. Dr. Krohn will now fully focus on his new leadership role with Akribion Genomics. Dr. Pelzer was previously Unit Head Enzymes & Biocatalysts at the company and has been with BRAIN Biotech for almost nine years. Dr. Pelzer enjoyed a broad education in biocatalysis, microbiology and molecular biology at the Research Centre Juelich with a focus on industrial enzyme technology. In addition to his experience in relevant fields, he demonstrated strong leadership skills along his whole career path. In addition, Dr. Martin Langer will expand his current business development responsibilities and will be appointed Managing Director and Executive Vice President of the BioScience segment at the Zwingenberg site. Dr. Langer was one of the first employees at BRAIN Biotech and accordingly has several decades of corporate experience. Alexander Pelzer and Martin Langer will take joint responsibility for further developing the R&D center in Zwingenberg into a customer-preferred provider for integrated biotechnology solutions.
공시 • Nov 04BRAIN Biotech AG, Annual General Meeting, Mar 08, 2023BRAIN Biotech AG, Annual General Meeting, Mar 08, 2023.
Breakeven Date Change • Oct 01Forecast to breakeven in 2025The 4 analysts covering BRAIN Biotech expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €5.08m in 2025. Average annual earnings growth of 73% is required to achieve expected profit on schedule.